Related Experiment Video
Updated: May 26, 2026
09:18
Assessing the Putative Anticryptococcal Properties of Crude and Clarified Extracts from Mollusks
Published on: December 2, 2022
Antifungal activity of plumericin and isoplumericin
Dharmendra Singh1, Umakant Sharma, Parveen Kumar
1Department of Laboratory Medicine, All India Institute of Medical Sciences, New Delhi-110 029, India.
Natural Product Communications
|January 10, 2012
Summary
This study found plumericin, a compound from Plumeria bicolor, effectively inhibits Candida species and Cryptococcus neoformans in vitro. Its potent antifungal activity suggests potential for treating candidiasis and cryptococcosis.
Area of Science:
- Mycology
- Pharmacology
- Natural Products Chemistry
Background:
- Candida species and Cryptococcus neoformans are significant fungal pathogens.
- Antifungal drug resistance necessitates the discovery of novel therapeutic agents.
- Plumeria bicolor is a plant with potential medicinal properties.
Purpose of the Study:
- To evaluate the in vitro antifungal activity of Plumeria bicolor extracts and its constituents.
- To determine the Minimum Inhibitory Concentration (MIC) and Minimum Fungicidal Concentration (MFC) against pathogenic fungi.
- To compare the efficacy of plumericin and isoplumericin with a standard antifungal drug.
Main Methods:
- The chloroform extract of Plumeria bicolor was prepared.
- Phytoconstituents plumericin and isoplumericin were isolated and identified.
- Antifungal activity was assessed against Candida species and Cryptococcus neoformans using MIC and MFC assays.
- Nystatin was used as a positive control.
Main Results:
- Plumericin demonstrated significant in vitro antifungal activity against all tested Candida species (C. albicans, C. krusei, C. glabrata, C. tropicalis) and Cryptococcus neoformans.
- The antifungal potency of plumericin was superior to isoplumericin and the standard drug nystatin.
- MIC and MFC values indicated fungicidal activity of plumericin.
Conclusions:
- Plumericin exhibits potent in vitro antifungal activity against key fungal pathogens.
- Plumericin shows promise as a potential drug candidate for treating candidiasis and cryptococcosis.
- Further investigation into plumericin's therapeutic potential is warranted.
Related Concept Videos
01:15Antifungal Agents
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
01:29Fungal Group Zygomycota
Zygomycota, previously classified as a distinct fungal group, are primarily terrestrial, saprophytic molds that play a crucial role as decomposers. Recent phylogenetic studies have revealed that these fungi are now divided into two major clades — Mucoromycota, which includes many symbiotic species, and Zoopagomycota, which primarily consists of parasitic and pathogenic fungi. These groups exhibit distinct ecological roles and reproductive strategies while sharing key structural and...